Clinical Trial

Soluble Immune Checkpoints in Intra-Abdominal Infections

Completed
View on ClinicalTrials.gov →
Summary
Intraabdominal infections is a life-threatening syndrome with a high incidence and a significant economic burden. The early-stage cytokine storm and the late-stage immunosuppression contribute to the mortality of sepsis. Immune checkpoints expressed on lymphocytes and antigen-presenting cells (APCs) play a crucial role in the pathogenesis of sepsis by regulating immune dysfunction. Specific therapies targeting immune checkpoints have shown great potential in animal and preclinical studies, paving the way for further clinical research. In this study, the significance of serum immune checkpoints - sCD25 (IL-2Ra), 4-1BB, B7.2 (CD86), Free Active TGF-beta1, CTLA-4, PD-L1, PD-1, Tim-3, LAG-3, and Galectin-9 - will be investigated in patients with intraabdominal infection.
Trial Details
NCT Number NCT07689266
Lead Sponsor Istanbul Training and Research Hospital
Conditions Intra Abdominal Infections
Enrollment 75 participants
Start Date 2023-12-01
Primary Completion 2024-12-31 (estimated)
Study Completion 2025-08-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-08